cancer_navi· @cancer_navi · X·· 2026-04-21Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
Breaking news from AACR. In previously treated KRAS G12D mutation-positive advanced non-small cell #lung cancer, the RAS(ON)G12D inhibitor zoldonrasib, which targets the GTP-bound state—the active form of the RAS G12D isoform—demonstrated tolerability in an ongoing phase 1 trial
Heat 5 · 5 likes · 0 replies · 0 reposts
Source: cancer_navi · x.com